Hamad Medical Corporation, Doha, Qatar.
Annamalai University, Rajah Muthiah Medical College, Chidambaram, India.
J Med Microbiol. 2024 Aug;73(8). doi: 10.1099/jmm.0.001861.
The frequency of multidrug-resistant organisms (MDROs) in hospitals and the risk of delaying effective treatment result in the culture of respiratory secretions for nearly all patients with suspected pneumonia. Culture delays contribute to over prescribing and use of broader spectrum antibiotics. The need for improved rapid diagnostics for early assessment of suspected hospital pneumonia. To validate a new metric, enhanced Gram stain (EGS), to provide a rapid diagnostic test of high diagnostic accuracy that could be assessed in clinical trials of the use of antibiotics in suspected pneumonia. Ninety-two residual lower respiratory samples previously tested by culture and Gram stain were re-tested by 16S ribosomal DNA real-time polymerase chain reaction (16S qPCR) and reported as a combined metric with Gram stain termed EGS. The EGS was assessed for diagnostic accuracy, standard performance measurements and correlation against culture. For samples with discordance between culture and EGS, 16S ribosomal DNA whole operon sequencing (16S rDNA WOS) was used for test resolution. An amended EGS (A-EGS was reassessed against culture. Gram stain, 16S qPCR, EGS and A-EGS had respective diagnostic accuracies of 77.01 %, 82.76 %, 84.04 % and 94.19 %. The same platforms had respective correlation with culture of = 0.67, = 0.71, = 0.81 and = 0.89. EGS had the highest negative predictive value (NPV) of 93.18 % (81.99 %-97.62 %). Adding an 16S qPCR result is achievable in most routine laboratories and, combined with Gram stain, could improve early decision-making in patients with suspected hospital pneumonia. EGS could improve early decision-making in patients with suspected hospital pneumonia and could be assessed in clinical trials. The 16S rDNA WOS results in the A-EGS also supported the use of pathogen genomic sequencing in early decision making of suspected pneumonia.
医院中多药耐药菌(MDRO)的频率以及延迟有效治疗的风险导致几乎所有疑似肺炎患者都需要进行呼吸道分泌物培养。培养的延迟导致过度处方和使用更广泛的抗生素。需要改进快速诊断方法,以便早期评估疑似医院肺炎。为了验证一种新的指标,增强革兰氏染色(EGS),以提供一种快速诊断测试,具有高诊断准确性,可以在疑似肺炎使用抗生素的临床试验中进行评估。92 个残留的下呼吸道样本先前通过培养和革兰氏染色进行了测试,然后通过 16S 核糖体 DNA 实时聚合酶链反应(16S qPCR)进行了重新测试,并与革兰氏染色一起报告为称为 EGS 的综合指标。评估了 EGS 的诊断准确性、标准性能测量值以及与培养的相关性。对于培养和 EGS 之间存在差异的样本,使用 16S 核糖体 DNA 全操纵子测序(16S rDNA WOS)进行测试解析。对经修正的 EGS(A-EGS)进行了重新评估。革兰氏染色、16S qPCR、EGS 和 A-EGS 的诊断准确性分别为 77.01%、82.76%、84.04%和 94.19%。相同的平台与培养的相关性分别为 = 0.67、= 0.71、= 0.81 和 = 0.89。EGS 的阴性预测值(NPV)最高,为 93.18%(81.99%-97.62%)。在大多数常规实验室中都可以实现添加 16S qPCR 结果,并且与革兰氏染色相结合,可以改善疑似医院肺炎患者的早期决策。EGS 可以改善疑似医院肺炎患者的早期决策,并可以在临床试验中进行评估。A-EGS 的 16S rDNA WOS 结果也支持在疑似肺炎的早期决策中使用病原体基因组测序。